
    
      Three hundred and twenty-four (324) eligible adult subjects with diabetes mellitus with
      central DME involvement will be randomized 1:1 to intravitreal treatment with MYL-1701P or
      EyleaÂ®. Subjects will receive the assigned treatment until Week 48.

      All subjects will return to clinic every 4 weeks to assess safety, efficacy and to guide
      treatment. There will be additional visits during the study as specified in the study
      schedule for safety and pharmacokinetic evaluation.

      Pharmacokinetics (PK) and Immunogenicity will be assessed in the subjects participating in
      the study.
    
  